Biotechnology

Tenaya Therapeutics

Tenaya Therapeutics' Stock Sale Leads to a 42.3% Drop in Share Price

Cory Jubinville Reiterates Buy Rating on Tenaya Therapeutics

Tenaya Therapeutics released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -0.1537)

Tenaya Therapeutics released FY2025 9 Months Earnings on November 10, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.5116

Tenaya Therapeutics released FY2025 Semi-Annual earnings on August 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3674 (forecast USD -0.29)

Tenaya Therapeutics released FY2025 Q2 earnings on August 6 (EST), actual EPS USD -0.143 (forecast USD -0.2042)

Tenaya Therapeutics Receives Consensus Buy Ratings

CEO of Tenaya Therapeutics Disposes of Common Stock

Tenaya Therapeutics released FY2025 Q1 earnings on May 7, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.2445 (forecast EPS USD -0.1971)

Tenaya Therapeutics reports a first-quarter operating loss of $27.538 million

Tenaya Therapeutics Presents Midline Data on ARVC

Tenaya Therapeutics Inc Approves Restructuring Plan to Reduce Cash Expenditures

Tenaya Evaluates TN-201 as a Potential Therapy for Hypertrophic Cardiomyopathy

Tenaya Therapeutics Inc submits mixed shelf registration statement for up to $300 million

Tenaya Therapeutics released FY2024 Q4 earnings on March 10 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2758 USD (forecast -0.315 USD)

Tenaya Therapeutics released FY2024 annual earnings on March 10 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.3101 USD (forecast -1.3512 USD)

Tenaya Therapeutics, Inc. Plans Public Offering of Common Stock and Warrants to Raise Funds for Heart Disease Treatment

Tenaya Therapeutics to Announce Initial Data from TN-201 Gene Therapy on December 17, 2024

Tenaya Therapeutics released FY2024 Q3 earnings on November 6 EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2975 (forecast USD -0.3571)

Tenaya Therapeutics released FY2024 9 Months Earnings on November 6, 2024 (EST), actual revenue USD 0, actual EPS USD -1.0388

Vision Marine Tech

AMC Robotics

B Riley Financial

Cementos Pacasmayo Saa 

Everbright Digital

Adagio Medical

Emerald

ChowChow Cloud

AdvisorShares MSOS 2x Daily ETF

Biodexa Pharmaceuticals

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap